

Vitamin D₃ analogue

DESCRIPTION: Cholecalciferol is the naturally occurring form of Vitamin D, also called Vitamin D₃. It is produced from 7- dehydrocholesterol, a sterol present in mammalian skin, by ultraviolet irradiation.

Calciferol is involved in bone fixation of calcium. It is indicated in prevention and treatment of Vitamin D deficiencies.

D4U Drops:

Each ml contains:

COMPOSITION:

D4U Injection:

Each ml contains:

Cholecalciferol (Vitamin D₃) B.P.5mg Cholecalciferol (Vitamin D₃) B.P.5mg Genix Specs.



DOSAGE AND ADMINISTRATION:

Prevention: Infants receiving Vitamin enriched milk: 1/2 Ampoule (i.e. 100.000 I.U.) every 6 months.

Nursed infants or infants not receiving Vitamin D enriched milk or young children upto 5-years of age: 1 Ampoule (i.e. 200,000 I.U.) every 6-months.

Adolescents: 1 Ampoule (i.e. 200.000 I.U.) every 6-months during winter.

Pregnancy: ½ Ampoule (i.e. 100,000 I.U.) from 6th or 7th month of pregnancy.

Elderly: ½ Ampoule (i.e. 100,000 I.U.) every 3-months, Digestive disorders, concomitant treatment with anti-epileptics, particular conditions not prescribed above: ½ or 1 Ampoule every 3 or 6 months.

Vitamin D Deficiency: 1 Amooule (i.e. 200.000 I.U.), which can be renewed once 1 to 6 months later.

PEDIATRIC DOSE OF DROPS:

Usual Pediatric Dose for Vitamin D Insufficiency:

Treatment of Vitamin D deficiency and/or rickets:

Infants 1 to 12 months: 1000 to 5000 International units/day for 2 to 3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day.

Children older than 12 months: 5000 to 10,000 international units/day for 2 to 3 months; once radiologic evidence of healing is observed, dose should be decreased to 400 international units/day.

Prevention and treatment of Vitamin D Deficiency in cystic fibrosis:

Alternate dosing: Infants less than 1 year; 8000 international units/week, Children older than 1 year; 800 international units/day.

Medium Dose Regimen: Patients less than 5 years: 12,000 international units/week for 12 weeks.

Patients 5 years or older: 50,000 international units/week for 12 weeks.

High Dose Regimen: Patient less than 5 years: 12,000 international units twice weekly for 12 weeks.

Patient 5 years or older: 50.000 international units twice weekly for 12 weeks.

WARNING & PRECAUTIONS: This drug must not be used in the following cases: Hypersensitivity to any of the ingredients mainly to Vitamin-D. Hypercalcemia (abnormally high blood calcium levels), Hypercalciuria (excessive urinary elimination of calcium), Calcium lithiasis (kidney stones),


CONTRAINDICATIONS: Vitamin D should not be given to patients with hypercalcemia or evidence of Vitamin-D toxicity. Use of Vitamin D in patients with known hypersensitivity to Vitamin D (or drugs of the same class) or any of the inactive ingredient is contraindicated.

Preunancy and Lactation: This medicinal product can be prescribed during pregnancy or lactation if necessary. However it is preferable to consult your doctor before using this drug.

DRUG INTERACTIONS: Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins; as such it may impair intestinal absorption of any of Vitmain-D. Thiazides: Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with Vitamin-D causes hypercalcemia. Therefore, precautions should be taken when co-administration is necessary. Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias. Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of Vitamin D. Reductions in serum endogenous Vitamin D concentration have been observed following the administration of 300mg/day to 1200mg/day ketoconazole for a week to healthy men. Corticosteroids: A relationship of functional antagonism exists between Vitamin D analogues, which promote calcium absorption and corticosteroids, which inhibit calcium absorption. Phosphate-Binding Agents: Since Vitamin D also has effect on phosphate transport in the intestine, kidneys and bones, the dosage of phosphate binding agents must be adjusted in accordance with the serum phosphate concentration. Vitamin D: The co-administration of any of the Vitamin D analogues should be avoided as this could create possible additive effects and hypercalcemia. Calcium Supplements: Uncontrolled intake of additional calcium-containing preparations should be avoided. Magnesium: Magnesium-containing preparations (e.g., antacids) may cause hypermagnesemia and should therefore not be taken during therapy with Vitamin D by patients on chronic renal dialysis.

Overdosage: In the event of an overdosage vitamin D3, following symptoms may occur; headache, fatigue, slimming, growth, retardation, nausea. vomiting, excess of urines, intense thirst, arterial hypertension, In case of any symptoms inform your doctor immediately.

UNDESIREABLE AND UNPLEASENT EFFECTS: As with any medicine this product may produce unpleasant effects varying severity in some people. Consult your physician if any unwanted or unpleasant effect is observed.



INSTRUCTIONS: Store below 30°C. Protect from heat & light.

For Injection: Avoid freezing and injection should not be used if container is leaking, solution is cloudy or it contains un-dissolved particles.

PRESENTATION: D4U Injection are available in 1ml x 5 ampoules with ampoule breaker & leaflet. D4U Oral Drops are available in 10ml amber green bottle & tamper evident dropper & leaflet.

Manufactured by:




44.45-B. Korangi Creek Road, Karachi-75190, Pakistan, UAN: +92-21-111-10-10-11. Email: info@genixpharma.com

Manufactured for:

DANEEN Daneen Pharma (Pvt.) Ltd.

27-Sundar Industrial Estate, Sundar Raiwind Road Lahore, Pakistan. Tel: +92-42-35297781-2. Email: info@daneenpharma.com









182-816-02